EL7.AI
Stocks•13 August 2026•
1 min read

Small-Cap Q2 Results: BayFirst Reports Losses While Co-Diagnostics Expands in Saudi

Key Facts

1BayFirst Financial reported a net loss of $32.7 million for Q2 2026, driven by $41.5 million in asset resolution plan expenses.
2CV Sciences generated $3.0 million in revenue with a gross margin of 48.6% for the second quarter of 2026.
3Co-Diagnostics advanced its Saudi Arabian manufacturing strategy with site approval and a lease agreement in Sudair Industrial City.

Amid varying operational pressures for small-cap firms, three companies released their Q2 2026 financial results. BayFirst Financial reported a significant net loss of $32.7 million, primarily driven by $41.5 million in expenses related to an asset resolution plan. Meanwhile, CV Sciences generated $3.0 million in revenue with a gross margin of 48.6%, and Co-Diagnostics announced a strategic milestone in Saudi Arabia with the approval of a manufacturing site in Sudair Industrial City.

According to market data and financial reports, these results highlight diverging sectoral paths; BayFirst faced heavy losses due to structural adjustments, while CV Sciences experienced revenue pressure despite cost-cutting measures. In contrast, Co-Diagnostics is prioritizing regional expansion in the MENA region through localized production, standing out as a strategic pivot amidst the weaker financial performance reported by its peers in this cluster.

Investors should watch for further manufacturing updates from Co-Diagnostics in Saudi Arabia as a forward catalyst, alongside broader macro signals such as the Fed's Barkin speech scheduled for August 7, 2026, which may impact risk appetite for the small-cap sector.